Business Context and Reporting Period
This Form 8-K is a current report filed by Aziyo Biologics, Inc. (not Elutia Inc.) on December 30, 2022, covering events that occurred on December 23, 2022. The company is incorporated in Delaware and trades on The Nasdaq Capital Market under the symbol AZYO. The filing addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive employment agreements and does not contain financial performance data.
Material Changes
On December 23, 2022, the Company entered into Amended and Restated Employment Agreements with two named executive officers:
- Matthew Ferguson, Chief Financial Officer
- Thomas Englese, Chief Commercial Officer
These agreements amend the original employment contracts dated September 30, 2020. The primary change resets the employment term to commence on the date of the new agreement (December 23, 2022) and continue until terminated in accordance with the agreement's provisions. The original two-year term with an automatic one-year extension structure remains, but the start date is updated. No other changes to the terms were made.
Guidance, Outlook, and Risks
The filing does not contain management commentary on business outlook, financial guidance, or specific risk factors. It notes that the descriptions of the employment agreements are qualified in their entirety by reference to the full text of the agreements filed as Exhibits 10.1 and 10.2.
Investor Verification Checklist
- Verify the full terms of the Amended and Restated Employment Agreements by reviewing Exhibit 10.1 (Matthew Ferguson) and Exhibit 10.2 (Thomas Englese) attached to the filing.
- Confirm the specific termination provisions and severance details within the referenced exhibits, as the summary does not detail these clauses.
- Note the discrepancy in the request metadata: the filing is for Aziyo Biologics, Inc., not Elutia Inc.